文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2000 年至 2022 年期间,丹麦全国范围内基于人群的队列研究中,房颤及其并发症的终生风险的时间趋势。

Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study.

机构信息

Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

Diagnostic Centre, University Clinic for Development of Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.

出版信息

BMJ. 2024 Apr 17;385:e077209. doi: 10.1136/bmj-2023-077209.


DOI:10.1136/bmj-2023-077209
PMID:38631726
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11019491/
Abstract

OBJECTIVES: To examine how the lifetime risks of atrial fibrillation and of complications after atrial fibrillation changed over time. DESIGN: Danish, nationwide, population based cohort study. SETTING: Population of Denmark from 1 January 2000 to 31 December 2022. PARTICIPANTS: 3.5 million individuals (51.7% women and 48.3% men) who did not have atrial fibrillation at 45 years of age or older were followed up until incident atrial fibrillation, migration, death, or end of follow-up, whichever came first. All 362 721 individuals with incident atrial fibrillation (46.4% women and 53.6% men), but with no prevalent complication, were further followed up until incident heart failure, stroke, or myocardial infarction. MAIN OUTCOME MEASURES: Lifetime risk of atrial fibrillation and lifetime risks of complications after atrial fibrillation over two prespecified periods (2000-10 2011-22). RESULTS: The lifetime risk of atrial fibrillation increased from 24.2% in 2000-10 to 30.9% in 2011-22 (difference 6.7% (95% confidence interval 6.5% to 6.8%)). After atrial fibrillation, the most frequent complication was heart failure with a lifetime risk of 42.9% in 2000-10 and 42.1% in 2011-22 (-0.8% (-3.8% to 2.2%)). Individuals with atrial fibrillation lost 14.4 years with no heart failure. The lifetime risks of stroke and of myocardial infarction after atrial fibrillation decreased slightly between the two periods, from 22.4% to 19.9% for stroke (-2.5% (-4.2% to -0.7%)) and from 13.7% to 9.8% for myocardial infarction (-3.9% (-5.3% to -2.4%). No evidence was reported of a differential decrease between men and women. CONCLUSION: Lifetime risk of atrial fibrillation increased over two decades of follow-up. In individuals with atrial fibrillation, about two in five developed heart failure and one in five had a stroke over their remaining lifetime after atrial fibrillation diagnosis, with no or only small improvement over time. Stroke risks and heart failure prevention strategies are needed for people with atrial fibrillation.

摘要

目的:研究心房颤动和心房颤动后并发症的终生风险随时间的变化情况。

设计:丹麦全国性基于人群的队列研究。

设置:2000 年 1 月 1 日至 2022 年 12 月 31 日期间丹麦的人群。

参与者:350 万年龄在 45 岁及以上、无心房颤动的个体,随访至发生心房颤动、移民、死亡或随访结束,以先发生者为准。所有 362721 名患有心房颤动(46.4%为女性,53.6%为男性)但无现有并发症的患者进一步随访至发生心力衰竭、中风或心肌梗死。

主要观察指标:两个预设时间段(2000-10 年和 2011-22 年)内心房颤动和心房颤动后并发症的终生风险。

结果:2000-10 年,心房颤动的终生风险为 24.2%,2011-22 年为 30.9%(差异为 6.7%(95%置信区间为 6.5%至 6.8%))。心房颤动后最常见的并发症是心力衰竭,2000-10 年的终生风险为 42.9%,2011-22 年为 42.1%(-0.8%(-3.8%至 2.2%))。患有心房颤动的个体在没有心力衰竭的情况下失去了 14.4 年的生命。两个时期之间,心房颤动后中风和心肌梗死的终生风险略有下降,中风从 22.4%降至 19.9%(-2.5%(-4.2%至 -0.7%)),心肌梗死从 13.7%降至 9.8%(-3.9%(-5.3%至 -2.4%))。没有证据表明男性和女性之间的下降存在差异。

结论:在 20 多年的随访中,心房颤动的终生风险增加。在患有心房颤动的个体中,约五分之二的人在心房颤动诊断后会发生心力衰竭,五分之一的人会发生中风,而且随着时间的推移,这些风险没有或仅有微小的改善。需要针对患有心房颤动的人制定中风风险和心力衰竭预防策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679c/11019491/03d5691c84df/vinn077209.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679c/11019491/66554829ea42/vinn077209.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679c/11019491/03d5691c84df/vinn077209.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679c/11019491/66554829ea42/vinn077209.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679c/11019491/03d5691c84df/vinn077209.f2.jpg

相似文献

[1]
Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study.

BMJ. 2024-4-17

[2]
Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases.

Cochrane Database Syst Rev. 2025-5-6

[3]
Beta-blockers in patients without heart failure after myocardial infarction.

Cochrane Database Syst Rev. 2021-11-5

[4]
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Health Technol Assess. 2004-10

[5]
Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis.

Eur J Prev Cardiol. 2017-6-15

[6]
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Health Technol Assess. 2008-6

[7]
Urodynamics tests for the diagnosis and management of male bladder outlet obstruction: long-term follow-up of the UPSTREAM non-inferiority RCT.

Health Technol Assess. 2025-7

[8]
Temporal order of atrial fibrillation and acute myocardial infarction and associated prognosis in the Danish Diet, Cancer and Health cohort.

Open Heart. 2025-1-21

[9]
Exercise-based cardiac rehabilitation for adults with atrial fibrillation.

Cochrane Database Syst Rev. 2024-9-17

[10]
Colchicine for the primary prevention of cardiovascular events.

Cochrane Database Syst Rev. 2025-2-10

引用本文的文献

[1]
Improving the reporting on health equity in observational research (STROBE-Equity): extension checklist and elaboration.

BMJ. 2025-9-3

[2]
Patient Perspectives on the "Future Patient" Telerehabilitation Program for Atrial Fibrillation: Qualitative Study.

JMIR Cardio. 2025-8-19

[3]
Global burden of atrial fibrillation/atrial flutter and its attributable risk factors in adolescents and young adults, 1990-2021: insights from the global burden of disease study.

Ann Med. 2025-12

[4]
Comparative Risk of Major Bleeding With Concomitant Use of Oral Anticoagulants and Corticosteroid Bursts.

Clin Transl Sci. 2025-8

[5]
A Sphincter-like Function of Pulmonary Vein Ostia in Normal and Atrial Fibrillation Subjects.

J Cardiovasc Dev Dis. 2025-5-28

[6]
Genomic medicine for heart failure prediction in patients with atrial fibrillation.

Europace. 2025-7-1

[7]
[Surgical closure of the left atrial appendage for thromboembolism prophylaxis].

Herzschrittmacherther Elektrophysiol. 2025-6

[8]
Reasons for omitting anticoagulant treatment in patients with atrial fibrillation: an audit of patient records in general practice.

BMC Prim Care. 2025-5-15

[9]
Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation.

J Arrhythm. 2025-4-23

[10]
The Search Continues for Better Markers That Aid in the Diagnosis and Prevention of Atrial Fibrillation and its Complications.

Arq Bras Cardiol. 2025-3-21

本文引用的文献

[1]
Birth cohort effects on diagnosed atrial fibrillation incidence: nationwide cohort study from 1980 to 2018.

Heart. 2024-4-25

[2]
The Danish Atrial Fibrillation Registry: A Multidisciplinary National Pragmatic Initiative for Monitoring and Supporting Quality of Care Based on Data Retrieved from Administrative Registries.

Clin Epidemiol. 2023-12-22

[3]
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

J Am Coll Cardiol. 2024-1-2

[4]
Time trends in body mass index distribution in the general population in Denmark from 1987 to 2021.

Dan Med J. 2023-9-19

[5]
The bidirectional association between atrial fibrillation and myocardial infarction.

Nat Rev Cardiol. 2023-9

[6]
A comparison of statistical methods to predict the residual lifetime risk.

Eur J Epidemiol. 2022-2

[7]
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report.

J Am Heart Assoc. 2021-8-17

[8]
Temporal trends in cause-specific mortality among individuals with newly diagnosed atrial fibrillation in the Framingham Heart Study.

BMC Med. 2021-7-29

[9]
Estimation and modeling of the restricted mean time lost in the presence of competing risks.

Stat Med. 2021-4

[10]
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.

Eur Heart J. 2021-2-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索